Submit Manuscript  

Article Details


Clinical and Translational Challenges in Thyroid Cancer

Author(s):

Jorge Hernando*, Javier Ros, Alvaro Arroyo and Jaume Capdevila   Pages 1 - 14 ( 14 )

Abstract:


Thyroid cancer is the most common endocrine malignancy and it accounts for 1% of all newly diagnosed tumors. Approximately 10% of patients with differentiated thyroid carcinomas (DTC) and 30% with medullary thyroid carcinoma (MTC) will not be cured with locoregional treatment and will develop metastatic disease. In addition, one of the most aggressive solid tumors can arise from the thyroid gland, the anaplastic thyroid carcinoma, with a median overall survival of less than 6 months. Currently, only four drugs are approved for the treatment of DTC and MTC and several unmet needs are focusing the scientific discussions, including the resistant setting, the off-target side effects that may reduce the efficacy and the molecular knowledge-based combinations. In this review we aim to discuss the current molecular landscape and treatment of thyroid cancers, and the ongoing clinical and translational research lines focusing on new drugs and drug combinations to improve the inhibition of driver mutations, such as BRAF and RET, and how systemic therapies that improved outcomes of other cancer types, like immunotherapy and peptide receptor radionuclide therapy, may play a role in the future management of advanced thyroid cancers.

Keywords:

Thyroid cancer; Multi-Kinase Inhibitors; BRAF mutations; PAX8/PPARγ; RET inhibitors; immunotherapy; clinical trials

Affiliation:

Medical Oncology Department. Gastrointestinal and Endocrine Tumor Unit Vall d´Hebron University Hospital Vall Hebron Institute of Oncology (VHIO) Pg Vall d´Hebron 119-129 08035 Barcelona , Medical Oncology Department. Gastrointestinal and Endocrine Tumor Unit Vall d´Hebron University Hospital Vall Hebron Institute of Oncology (VHIO) Pg Vall d´Hebron 119-129 08035 Barcelona , Medical Oncology Department. Gastrointestinal and Endocrine Tumor Unit Vall d´Hebron University Hospital Vall Hebron Institute of Oncology (VHIO) Pg Vall d´Hebron 119-129 08035 Barcelona , Medical Oncology Department. Gastrointestinal and Endocrine Tumor Unit Vall d´Hebron University Hospital Vall Hebron Institute of Oncology (VHIO) Pg Vall d´Hebron 119-129 08035 Barcelona



Read Full-Text article